{"id":832,"date":"2025-01-22T19:04:41","date_gmt":"2025-01-22T19:04:41","guid":{"rendered":"https:\/\/www.nordicbioscience.com\/?post_type=biomarker-solutions&p=832"},"modified":"2025-06-06T09:02:59","modified_gmt":"2025-06-06T09:02:59","slug":"rheumatrace","status":"publish","type":"biomarker-solution","link":"https:\/\/www.nordicbioscience.com\/biomarker-solution\/rheumatology\/rheumatrace\/","title":{"rendered":"RheumaTrace\u2122"},"content":{"rendered":"
\n
\n
\n

RheumaTrace\u2122<\/h1>\n

RheumaTrace\u2122 is a next-generation biomarker panel developed to advance precision medicine in rheumatology. Built on over 30 years of research and more than 200 publications, it features seven biomarkers that capture key aspects of connective tissue degradation and immune activity. RheumaTrace\u2122 enables drug developers to track disease activity, predict treatment response, and identify target patient populations\u2014supporting smarter, faster decisions in clinical development.<\/p>\n

\n \n Order the RheumaTrace\u2122 panel \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/article>\n <\/div>\n<\/section>\n\n\n\n\n
\n \n
\n
\n
\n
\n

The RheumaTrace\u2122 biomarker panel<\/h2>\n \n\n <\/div>\n
\n
\n
\n
\n
\n
\n
\n

Introducing Nordic RheumaTrace\u2122: a breakthrough biomarker panel\u00a0for rheumatic diseases<\/a>. Backed by three decades of research and over 200 peer-reviewed publications, this panel features seven carefully selected biomarkers.<\/p>\n

These biomarkers delve into the complexities of connective tissue degradation and immune cell dynamics, providing invaluable insights for researchers and drug developers.<\/p>\n

By pinpointing the disease pathway and determining the optimal dosage for positive outcomes, our panel is at the forefront of precision medicine in rheumatology.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n <\/div>\n <\/div>\n

\n \n Browse RheumaTrace\u2122 panel \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/article>\n
\n
\"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n
\n \n
\n
\n
\n
\n

Biomarkers in the RheumaTrace panel\u2122<\/h2>\n \n\n <\/div>\n
\n

The\u00a0RheumaTrace\u2122\u00a0<\/strong>biomarker panel for rheumatological diseases (RMDs) has been developed based on 3 decades of research and more than 200 peer-reviewed publications. The panel comprises\u00a0seven distinct biomarkers, carefully selected to encompass the intricacies of connective tissue degradation and immune cell dynamics.<\/p>\n

Together, these biomarkers offer researchers and drug developers invaluable insights into\u00a0disease activity,\u00a0<\/b>the\u00a0trajectory of disease progression,\u00a0<\/b>andthe efficacy of therapeutic interventions. By accurately identifying the critical pathway of the disease and the optimal dosage required to elicit a positive response, our panel\u00a0represents a cutting-edge solution for precision medicine in rheumatology.<\/p>\n <\/div>\n <\/div>\n <\/article>\n

\n \"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n
\n \n
\n
\n
\n
\n

Benchmark doses & drugs with RheumaTrace\u2122<\/h2>\n \n\n <\/div>\n
\n

<\/p>\n

The biomarkers in\u00a0RheumaTrace\u2122<\/strong>\u00a0are directly linked to the critical path of the disease and respond rapidly – within days and weeks – to effective drug intervention.<\/p>\n

<\/p>\n

With a dose-dependent effect, the panel demonstrates that only\u00a0efficacious doses\u00a0<\/strong>of the drug reach clinically significant suppression, ultimately translating into a positive drug response.<\/p>\n

As such, our panel has proven to be a valuable tool for\u00a0dose-finding and efficacy prediction\u00a0<\/strong>in phase I\/II interventional trials, as well as insight into mode-of-mechanism in phase II\/III.<\/p>\n

The panel is likewise suitable for assessing and\u00a0comparing drug response in head-to-head<\/strong>\u00a0studies.<\/p>\n

Figure 1. <\/strong>RheumaTrace\u2122 shows pharmacodynamics and MoA<\/em><\/p>\n

<\/p>\n <\/div>\n <\/div>\n <\/article>\n

\n \"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n
\n \n
\n
\n
\n
\n

RheumaTrace\u2122 is a smart translational medicine tool<\/h2>\n \n\n <\/div>\n
\n

<\/p>\n

<\/p>\n

As a smart translational medicine tool,\u00a0RheumaTrace\u2122<\/strong>\u00a0provides valuable support for drug (re)positioning efforts.<\/p>\n

By including connective tissue destruction markers, which have been shown to be elevated in various inflammatory and autoimmune conditions, the\u00a0panel enables targeted patient identification for drug trials and therapy<\/strong>.<\/p>\n

Conversely, the absence of such markers in non-inflammatory conditions further enhances the panel’s specificity.<\/p>\n

With the ability to\u00a0accurately identify patient populations likely to respond to specific drugs<\/strong>, our panel represents a cutting-edge solution for personalized medicine in rheumatology.<\/p>\n

Figure 2. <\/strong>RheumaTrace\u2122 enables targeted patient identification
\n<\/strong><\/em><\/p>\n

<\/p>\n <\/div>\n <\/div>\n

\n \n Elevate your research with RheumaTrace\u2122 today! \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/article>\n
\n
\"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n\n
\n

Watch how the RheumaTrace\u2122 biomarkers work<\/h2>\n\n\n\n
\n